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HPV vaccines
• FDA-approved HPV vaccine recommended to age 45
• Adviosry Committee on Immunization Practices (ACIP) 
does not recommend vaccine for adults older than 26 
(CDC, 2019a)
Cervical Cytology (Pap Smears)
• Looks at precancerous and cancerous cells related to 
cervical cancer
• Recommend every 3 years (Kaiser Permanente, 2019a)
High-risk HPV (hrHPV)
• Provides higher sensitivity in detecting indicators of 
HPV-related cervical cancer
• Recommend every 5 years with the potential to extend 
interval time between screenings to reduce unnecessary 
treatment (Kaiser Permanente, 2019a; Vink et al., 2015)
Co-testing
• Pap smear and hrHPV testing
• Recommend every 5 years (Kaiser Permanente, 2019a)
Shift to High-rsk HPV testing as the main 
screening tool for middle-aged adult women
Advocacy and education of the 
effectiveness that hrHPV testing 
provides for this specific 
population 
(Mayo Clinic, 2018)
Pros Cons
hrHPV
Testing
• More effective and 
longer-lasting protection
• High negative predictive 
value (Olgilvie et al., 
2017)
• Potential for self-
collection (Olgilvie et 
al., 2017)
• Assumptions that it 
detects all cervical 
cancers (Flanagan, 
2018)
• Roche Cobas HPV 
test is the only FDA 
approved hrHPV
testing (Kaiser 
Permanente, 2019a)
Cotesting • Can lead to long-term 
savings (Felix et al., 
2016)
• Study showed co-
testing was costlier 
than hrHPV testing 
alone (Jin et al., 
2016)
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Findings
RecommendationProblem
• 90% of cervical cancers are caused by the Human 
Pappilomavirus (HPV)
• 2012-2016: Median age among women for HPV-related 
cervical cancer was 49 years old (CDC, 2019c)
Advocate for a change in screening to decease 
incidence and prevalence of HPV related 
cancer 
(Mayo Clinic, 2018)
